Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States.

导出 LinkOut

翻译打印收藏纠错

作者： Kenneth P,Klinker ^[1] ; Levita K,Hidayat ^[1] ; Eric,Wenzler ^[2] ; Joan-Miquel,Balada-Llasat ^[3] ; Mary,Motyl ^[1] ; C Andrew,DeRyke ^[1] ; Karri A,Bauer ^[1]

作者单位： Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA. ^[1] Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, 833 South Wood St., Room 164, Chicago, IL 60612, USA. ^[2] Department of Clinical Microbiology and Clinical Pathology, The Ohio State University Wexner Medical Center, 181 Taylor Ave., Columbus, OH 43203, USA. ^[3]

关键词 Enterobacterales Pseudomonas aeruginosa cefepime ceftolozane/tazobactam extended-spectrum β-lactamase imipenem/relebactam meropenem piperacillin/tazobactam susceptibility testing syndromic antibiogram

DOI 10.3390/antibiotics11050660

PMID 35625304

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Antibiotics (Basel, Switzerland)

2022年11卷5期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States.

Antibiotics (Basel, Switzerland)

相似文献

Antibiotics (Basel, Switzerland)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States.

Antibiotics (Basel, Switzerland)

相似文献

Antibiotics (Basel, Switzerland)

相关期刊

检索历史清除